BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The Emerging Risk of Peptides in Supplements LegitScript Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions